BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM)(BFRIW.US)

longbridge loading
Company Encyclopedia
View More
name
BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM)
BFRIW.US
News
View More

Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio?

Trip.com, Regencell Bioscience, and Atlassian were among the top 10 large-cap losers last week, with Regencell leading the decline at 42.08%. Other notable losers included Figma (-19.41%), Atlassian (-19.82%), and Trip.com (-20.19%) due to downgrades and investigations. Analysts have adjusted price targets for several companies, including Morgan Stanley lowering Figma's target from $65 to $48 and HubSpot's from $640 to $577. Overall, the tech sector faced broader weakness, impacting multiple stocks significantly.

benzinga_article·
US
TCOM
+0.77%
HK
09961
+0.73%
US
RGC
-8.75%
benzinga_article·
US
TCOM
+0.77%
HK
09961
+0.73%
US
RGC
-8.75%

How weight-loss drugs are destroying big snacking, erasing billions in sales

The rise of GLP-1 weight-loss drugs is significantly impacting the food and beverage industry, leading to a projected $48 billion reduction in spending by 2034. Consumers are reducing their snacking frequency and appetite, with major brands like PepsiCo and Mondelez facing declining sales. Traditional marketing strategies are failing as appetite suppression alters consumer behavior, challenging the business models of companies reliant on high-volume sales. Fast-food spending has also dropped among GLP-1 users, indicating a fundamental shift in consumption patterns.

Invezz·
US
PEP
-0.17%
US
MDLZ
-0.10%
Invezz·
US
PEP
-0.17%
US
MDLZ
-0.10%

2026 China FIC Innovation and Collaboration Summit at J.P. Morgan Healthcare Conference in San Francisco showcased Chinese pharmaceutical company achievements.

On January 16, 2026, during the J.P. Morgan Healthcare Conference in San Francisco, the 2026 China FIC Innovation & Collaboration Summit took place. The event, hosted by the ZFIC Alliance, convened key Chinese figures in the US city.

Unusual Whales·
Unusual Whales·

From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development

Chai Discovery, an AI startup founded in 2024, has quickly gained prominence in drug development, raising hundreds of millions and achieving a $1.3 billion valuation after its series B funding. Recently, it announced a partnership with Eli Lilly to utilize its AI software for developing new medicines. Chai's algorithm aims to enhance antibody development, positioning itself as a key player in the biotech industry. Despite skepticism from some veterans, investors like General Catalyst express confidence in Chai's potential to accelerate drug discovery and bring innovative medicines to market by 2027.

TechCrunch·
US
LLY
+0.53%
TechCrunch·
US
LLY
+0.53%

Pharmaceutical Stocks To Keep An Eye On - January 16th

Eli Lilly, Novo Nordisk, AbbVie, Pfizer, Abbott Laboratories, AstraZeneca, and BridgeBio Pharma are highlighted as key pharmaceutical stocks to watch, according to MarketBeat. These companies are involved in the research, development, and sale of various pharmaceutical products, with significant trading volumes recently. Investors should be aware of the volatility and risks associated with these stocks, particularly related to clinical trials and regulatory approvals, but they also present opportunities for substantial returns if successful in drug launches.

Market Beat·
US
ABBV
-0.31%
US
BBIO
0.00%
US
LLY
+0.53%
Market Beat·
US
ABBV
-0.31%
US
BBIO
0.00%
US
LLY
+0.53%
© 2026 Longbridge｜Disclaimer